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Transcutaneous vagus nerve 
stimulation and extinction of 
prepared fear: A conceptual non-
replication
Andreas M. Burger1,2, Ilse Van Diest2, Willem van der Does1, Marsida Hysaj1, Julian F. Thayer3, 
Jos F. Brosschot1 & Bart Verkuil1
Transcutaneous stimulation of the auricular branch of the vagus nerve (tVNS) may accelerate fear 
extinction in healthy humans. Here, we aimed to investigate this hypothesis in healthy young 
participants in a prepared learning paradigm, using spider pictures as conditioned stimuli. After 
a fear conditioning phase, participants were randomly allocated to receive tVNS (final N = 42) or 
sham stimulation (final N = 43) during an extinction phase. Conditioned fear was assessed using US 
expectancy ratings, skin conductance and fear potentiated startle responses. After successful fear 
acquisition, participants in both groups showed a reduction of fear over the course of the extinction 
phase. There were no between-group differences in extinction rates for physiological indices of fear. 
Contrary to previous findings, participants in the tVNS condition also did not show accelerated 
declarative extinction learning. Participants in the tVNS condition did have lower initial US expectancy 
ratings for the CS− trials than those who received sham stimulation, which may indicate an enhanced 
processing of safety cues due to tVNS. In conclusion, the expected accelerated extinction due to tVNS 
was not observed. The results from this study call for more research on the optimal tVNS stimulation 
intensity settings.
Increasing insights into the neurological underpinnings of fear have sparked an interest in neuromodulatory 
techniques aimed at enhancing fear extinction1. Notably, promising extinction-modulating effects have been 
found for various neurostimulation techniques that specifically target areas of the brain involved in extinction 
learning2. Among these techniques, stimulation of the vagus nerve (VNS) is of particular interest, as preliminary 
evidence from animal models and human fear conditioning studies point towards treatment-augmenting effects 
of VNS during exposure therapy3–8.
The first studies on the effects of vagus nerve stimulation on fear extinction were performed in rats. In two 
separate experiments, Peña and colleagues demonstrated that rats who received VNS displayed less freezing after 
extinction training than rats who had undergone sham surgery3,4. Decreased fear responses were also found dur-
ing fear retention, two weeks after the initial extinction training3. These results were later replicated by the same 
research group, who showed that VNS improved the extinction of fear in rats by increasing the activation of the 
medial prefrontal cortex – basolateral amygdala pathway8.
VNS as a neuromodulatory add-on to extinction learning in humans has been an understudied subject up 
until now, because until recently VNS required surgical implantation of a neurostimulator. Recent studies have 
indicated that electrical stimulation of the concha of the left outer ear is a safe method to stimulate the auricular 
branch of the vagus nerve9. This transcutaneous VNS (tVNS) has similar effects on brain activation patterns as 
invasive VNS10 and increases performance in memory tasks and other cognitive tasks11,12. Although the working 
mechanisms of tVNS are currently still poorly understood13, invasive VNS is associated with the modulation of 
several neurotransmitters that could play an integral role in associative learning and memory. Firstly, VNS has 
been shown to increase levels of gamma-aminobutyric acid (GABA)14 and is associated with increased GABA 
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receptor density15 in humans. GABA is the principal inhibitory neurotransmitter in the brain, and is associated 
with dampening fear learning. Although research on the effects of GABAergic activity on fear extinction is still 
somewhat limited, preliminary evidence suggests that increased GABAergic signaling would lead to decreased 
extinction learning and memory consolidation (for a review, see16). As such, the effects of invasive and transcuta-
neous VNS are unlikely to be mediated by GABAergic effects of the stimulation, as this would produce a general 
slowing in extinction rates, which is opposite of what has been found in previous studies16. Instead, a more likely 
working mechanisms for the effects of tVNS is through its afferent connection to the nucleus tractus solitaries 
(NTS), which activates the locus coeruleus to secrete norepinephrine (NE)17–21. NE is an important determinant 
of the extent to which salient (eg., threat and safety) memories are first encoded and subsequently consolidated 
in long term memory22,23. Importantly, the effects of NE on memory have been shown to be associated with acti-
vation of peripheral vagal afferents24,25 and thus provide a physiological basis for the potential effects of VNS on 
fear extinction in the present study.
The effects of tVNS on fear extinction in humans have been assessed in three previous studies. In the first 
study (N = 31)6, using a two-day protocol, participants who received tVNS showed accelerated declarative fear 
extinction learning compared to those who received sham stimulation on day one. No effects on retention of fear 
memories 24 h after extinction training were found. Effects of tVNS on physiological indices of fear could not be 
assessed due to technical issues and a lack of differential fear conditioning during the fear acquisition phase. A 
subsequent study (N = 39) used a three-day protocol with acquisition, extinction and retention of extinction on 
day 1, 2 and 3 respectively7. Participants who received tVNS again showed accelerated declarative fear extinction 
and no effects 24 h after fear extinction. In this study, no effects of tVNS on physiological indices of fear extinction 
were found, possibly indicating that tVNS affects fear extinction primarily via hippocampal, declarative pathways. 
Finally, another study tested the effects of tVNS on contextual fear conditioning in a virtual reality environment 
(N = 75, divided into a sham, tVNS, and no stimulation group)26. The study used a three day protocol. Contrary 
to the cue conditioning studies, no effects of tVNS were found on either declarative or physiological indices of 
fear, and no effects were found on fear retention. One possible caveat of these studies was the limited sample size, 
which reduced the statistical power to detect meaningful differences.
In the current study, we aimed to assess the effects of tVNS on both declarative and physiological fear extinc-
tion of cue-conditioned fear in a sample large enough to provide us with adequate statistical power to detect 
meaningful effects. Fear acquisition and extinction phases were conducted on the same day, similarly to one of 
our previous studies6.We conducted a randomized single-blinded controlled trial to compare the effects of tVNS 
and sham stimulation during the extinction of fear. Pictures of spiders were used as CS, as previous studies have 
indicated that these evolutionarily relevant stimuli lead to more pronounced fear responses and delayed fear 
extinction27. Similarly, other changes to the experimental paradigm were made, including the addition of a back-
ground noise and increased startle probe intensity (cf.28). High-intensity auditory stimuli are known to increase 
subjective and physiological arousal29,30, which in turn strengthens fear conditioning and subsequently slows 
down fear extinction31. These procedural changes were implemented to slow down fear extinction, thus allowing 
for a stronger differential effect of tVNS compared to sham stimulation. We hypothesized that tVNS would accel-
erate fear extinction, both on a declarative and a physiological level.
Results
Demographics. Out of the original ninety-seven participants, 1 participant was excluded because she wanted 
to stop the experiment pre-emptively out of fear for the spider pictures used as conditioned stimuli in the exper-
iment. 4 participants had to be excluded due to mechanical failures with either the computer (n = 1), the shock 
device (n = 2) or the tVNS device (n = 1). Finally, 7 participants were excluded because they had difficulty under-
standing the CS-US contingency during the Acquisition phase. Specifically, these participants either did not show 
higher average US-expectancy ratings for the final two CS+ trials than for the final two CS− trials (n = 4), or 
they reported US expectancy ratings below 50% for the CS+ trials during the final two trials (n = 3). The analyses 
described in this article were performed on the data of the remaining 85 participants (NtVNS = 42 (out of which 5 
were male), NSham = 43 (out of which 9 were male), Mage = 21.01 (SD = 1.87)).
As displayed in Table 1, there were no significant differences between experimental groups on background 
variables that may affect fear conditioning and extinction. Although participants in the tVNS group scored higher 
on the Abbreviated Spider Phobia Questionnaire (A-SPQ, difference not significant), participants in both groups 
still scored well within the range of a healthy sample32. Participants’ scores on trait worry (assessed using the Penn 
State Worry Questionnaire or PSWQ) and trait anxiety (assessed using the State-Trait Anxiety Questionnaire or 
STAI-Trait) were also comparable to norm scores from healthy college students or community samples33. State 
anxiety (assessed through the STAI-State) were slightly elevated compared to healthy college students or com-
munity samples (Mhealthy norm = 35.2, SD = 8.4), but still well below state anxiety scores reported by clinical patient 
populations (Mpsychiatry patients = 56.4, SD = 13.8)34. Since these questionnaires were administered shortly after the 
acquisition phase, the elevated STAI-State scores in both groups may be a consequence of the fear conditioning 
procedure. Finally, no between-group differences were found on ratings of positive or negative mood.
No between-group differences were found on resting HR or HRV, which was assessed prior to the acquisition 
phase. Additionally, no differences were found after the Acquisition phase, when participants were asked to rate 
the unpleasantness of the US (see Table 1).
Acquisition. Multilevel mixed model analyses were used to assess fear and extinction learning in our partic-
ipants in terms of both self-reports and physiological outcomes. For a more detailed description of this statistical 
procedures, please refer to Statistical Analyses in the Methods section.
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Expectancy Ratings. Participants showed clear signs of differential fear learning on US expectancy ratings dur-
ing the acquisition phase, as reflected by the LogTrial*CStype interaction, b = 30.80, t(1269) = 11.74, p < 0.001 
(see Table 2). Participants successfully learned that the CS− was safe, as reflected in the significant decrease in 
US expectancy ratings, b = 19.55, t(1269) = −10.05, p < 0.001. The significant main effect of CStype shows that 
US expectancies for the to-be-conditioned CS+ were already higher from the first trial, b = 25.06, t(1269) = 5.11, 
p < 0.001. This apparent ‘prior knowledge’ of the CS-US contingency can easily be explained by the standardized 
presentation order of CSs at the start of the acquisition phase: every acquisition phase started with a CS− trial, 
followed by a non-reinforced CS+ trial. Participants were instructed that one CS trial would never be followed 
by a shock, and therefore likely deduced that since the first trial was not followed by a shock, the second picture 
they saw would likely be the CS+.
As expected, we found no effects of Condition on US expectancy ratings during acquisition (all ps > 0.05).
Electromyography. Participants’ EMG responses reflected successful differential fear conditioning during the 
acquisition phase, as indicated by the significant differential decrease of CS− trials compared to CS+ trials, 
b = −0.58, t(1853) = −1.96, p = 0.05, as well as the differential decrease of ITIs compared to CS+ trials, b = −1.45, 
t(1853) = −4.87, p < 0.001 (see Table 3). There were no significant differences in EMG responses between the 
CS+ and the CS− or the CS+ and the ITI at the start of the acquisition phase (both ps > 0.05).
There were no significant between-group differences in EMG during the acquisition phase (all ps > 0.05).
Skin Conductance Responses. Participant’s SCR reflected a clear differential learning curve, where SCR 
habituated over time for both CS+ and CS− trials as reflected by the main effect of LogTime, b = −0.17, 
t(1224) = −10.21, p < 0.001, but CS+ trials showed a differential increase compared to CS− trials over the course 
of the acquisition phase, b = 0.08, t(1224) = 4.87, p < 0.001 (see Table 4). Initial responses to the CS+ were lower 
than to the CS−, as reflected by the main effect of CStype, b = −0.08, t(1224) = −2.89, p = 0.01. The initial dif-
ference between CStypes likely reflects the non-randomized initial order of CS presentations: the first trial of the 
acquisition phase was always a CS− trial.
There were no significant between-group differences in SCR during the acquisition phase (all ps > 0.05).
Extinction. Expectancy Ratings. Participants in both groups showed a clear differential declarative fear 
response at the start of the extinction phase, as reflected in the significant main effect of CStype, b = 29.56, 
t(1949) = 5.36, p < 0.001 (see Table 2). US expectancy ratings for both CS types decreased over the course of the 
tVNS
M(SD)
Sham
M(SD) p
PSWQ 47.07 (8.59) 46.21 (9.98) 0.63
STAI state 41.83 (10.21) 41.28 (9.80) 0.95
STAI trait 38.44 (7.46) 37.51 (6.35) 0.48
A-SPQ 4.44 (3.43) 3.09 (2.78) 0.05
Positive mood 57.15 (15.41) 56.92 (19.35) 0.95
Negative mood 29.74 (18.25) 27.81 (18.23) 0.63
US unpleasantness Rating 65.14 (15.42) 63.54 (13.72) 0.61
Resting HRV (RMSSD) 45.61 (23.86) 43.91 (24.70) 0.75
Resting HR 75.10 (11.20) 76.64 (13.56) 0.57
Table 1. Descriptive statistics. Note. PSWQ: Penn State Worry Questionnaire, STAI-S: State-Trait Anxiety 
Questionnaire, A-SPQ: abbreviated Spider Phobia Questionnaire, US: Unconditioned stimulus, HRV: heart rate 
variability (Root mean square of the successive differences), HR: heart rate. Measurements of resting HR(V) 
were performed prior to the Acquisition phase. Between-group differences were tested using independent-
samples t-tests.
Predictor Acquisition Extinction
Intercept 40.70 (3.67)** 40.62 (4.18)**
CStype 25.06 (4.91)** 29.56 (5.51)**
LogTrial −19.55 (1.94)** −13.62 (1.64)**
LogTrial*CStype 30.80 (2.62)** −11.61 (2.32)**
Condition −2.32 (5.22) −9.50 (5.95)*
Condition*CStype 0.70 (6.98) 10.08 (7.84)
Condition*LogTrial 2.42 (2.77) 3.16 (2.33)
Condition*LogTrial*CStype −1.33 (3.73) − 0.97 (3.30)
Table 2. Regression weights and standard errors for mixed model analyses predicting US expectancy ratings in 
Acquisition and Extinction phases. Note. Reference category for CStype is the CS− trial type. All analyses on the 
effects of tVNS were conducted using one-sided hypothesis tests. *p < 0.05, **p < 0.001.
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extinction phase, b = −13.62, t(1949) = −8.30, p < 0.001. Expectancy ratings for CS+ trials showed a stronger 
decline than CS− trials, b = −11.61, t(1949) = −5.00, p < 0.001, indicating extinction learning.
There were no significant effects of Condition on learning curves for CS+ trials or CS− trials (both 
p > 0.05). However, there was a significant main effect of Condition on US expectancy ratings, b = −9.51, 
t(83) = −1.60, p = 0.05, δ = 0.36, reflecting lower US expectancy ratings in the tVNS condition. This main effect 
of Condition should be interpreted with caution, as the regression weights of the non-significant interactions 
of Condition*LogTrial (b = 3.16, t(1949) = 1.36, p = 0.91) and Condition*CStype (b = 10.09, t(1949) = 1.29, 
p = 0.90) indicate that the significant effect of Condition specifically reflects lower US expectancy ratings in the 
tVNS condition for CS− trials at the start of the extinction phase (see Fig. 1).
Electromyography. Participants showed strong overall startle responses at the start of the extinction phase, 
irrespective of CStype, as indicated by the overall intercept, b = 56.10, t(2799) = 70.52, p < 0.001 (see Table 3). 
They displayed a significant differential fear response to the CS+ compared to the ITI, b = 4.41, t(2799) = 3.92, 
p < 0.001. However, they did not show differential responding when comparing the CS+ trial to the CS− trials, 
b = 1.12, t(2799) = 0.99, p = 0.32, possibly indicating a generalization of the fear memory. In subsequent trials, we 
see a significant decrease in startle responses as indicated by the main effect of Trial, b = −1.24, t(2799) = −10.38, 
p < 0.001. However, there was no significant differential learning curve for CS+ trials either in comparison to ITIs 
or CS− trials (both p > 0.05). Thus, although participants displayed a strong general decrease in fear potentiated 
startle responses, participants did not show differential extinction learning.
There were no significant effects of Condition on initial EMG or on EMG learning curves over the course of 
the extinction phase (all p > 0.05, see Table 3 for regression weights).
Skin Conductance Responses. Participants did not show significant differential fear responses at the start 
of the extinction phase (main effect CStype, p = 0.67, see Table 4). Specifically, as displayed in Fig. 1, partici-
pants in both conditions had larger SCR at the start of the extinction phase compared to the end of the acqui-
sition phase, irrespective of CStype. Over the course of the extinction phase, SCR decreased significantly, 
b = −0.01, t(1875) = −4.00, p < 0.001, irrespective of CS type (interaction CStype*Trial, p = 0.64). Although this 
non-differential reduction in SCR may reflect the extinction of fear, it is difficult to disentangle this effect from a 
Predictor Acquisition Extinction
Intercept 57.03 (0.88)** 56.10 (0.80)**
CStypeCS− −1.76 (1.25) 1.12 (1.12)
CStypeITI −1.51 (1.25) −4.41 (1.12)
Trial −0.16 (0.21) −1.24 (0.12)**
Trial*CStypeCS− −1.45 (0.30)* −0.09 (0.17)
Trial*CStypeITI −0.58 (0.30)** −0.07 (0.17)**
Condition 0.02 (1.26) −0.47 (1.13)
Condition*CStypeCS− 0.61 (1.78) −1.32 (1.60)
Condition*CStypeITI 0.27 (1.78) −0.02 (1.59)
Condition*Trial −0.37 (0.30) 0.13 (0.17)
Condition*Trial*CStypeCS− 0.64 (0.42) 0.03 (0.24)
Condition*Trial*CStypeITI 0.18 (0.42) 0.13 (0.24)
Table 3. Regression weights and standard errors for mixed model analyses predicting EMG in Acquisition and 
Extinction phases. Note. Reference category for CStype is the CS+ trial type. All analyses on the effects of tVNS 
were conducted using one-sided hypothesis tests. *p < 0.05, **p < 0.001.
Predictor Acquisition Extinction
Intercept 0.41 (0.04)** 0.13 (0.02)**
CStype −0.08 (0.05)** 0.01 (0.02)
Triala −0.17 (0.02)** −0.01 (0.002)**
Triala*CStype 0.08 (0.02)** −0.001 (0.002)
Condition −0.05 (0.05) −0.02 (0.03)
Condition*CStype −0.01 (0.03) 0.01 (0.02)
Condition* Triala 0.02 (0.02) 0.004 (0.003)
Condition* Triala 
*CStype −0.002 (0.02) −0.002 (0.003)
Table 4. Regression weights and standard errors for mixed model analyses predicting SCR in Acquisition and 
Extinction phases. Note. Reference category for CStype is the CS− trial type. All analyses on the effects of tVNS 
were conducted using one-sided hypothesis tests. *p < 0.05, **p < 0.001. aTrial variable was log transformed in 
the Acquisition model.
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more general habituation response that was also evident during the acquisition phase. There were no significant 
effects of Condition on initial SCR or on SCR learning curves over the course of the extinction phase (all p > 0.05, 
see Table 4 for regression weights).
Side-effects. Using a short form of seven potential side-effects that we have observed in prior studies, we 
asked participants to rate their sensations of the neurostimulation at the end of the extinction phase while the 
stimulation was still active. Although participants in the tVNS condition reported higher side-effect intensity 
levels on average, it should be noted that average side-effect ratings were relatively low in both groups (overall 
MtVNS = 2.20(0.65), MSham = 1.90(0.71), t(87) = −2.01, p = 0.05).
Exploratory Analyses. We conducted additional exploratory analyses to assess possible moderators of the 
effects of tVNS on US expectancy ratings during the extinction phase. Specifically, the questionnaires that partic-
ipants had completed in between the acquisition and extinction phases (PSWQ, STAI-S, STAI-T and SPQ), as well 
as baseline RMSSD, were added to the model described in section 3.2 to see whether they moderate the effects of 
tVNS on declarative fear extinction. These factors were selected as potential moderators because their underlying 
constructs (i.e. perseverative cognition, state and trait anxiety, and vagal tone) have been associated with fear and 
extinction learning in previous studies (e.g.35–38). All factors were added separately to the model, both as continu-
ous and as median-split variables. However, none of these variables improved the overall model fit or resulted in 
significant interactions between the moderator and Condition. None of the possible moderators provided main 
effects for US expectancy ratings, either. Thus, we can conclude that in our current sample, RMSSD nor anxiety at 
baseline significantly affected the effects of tVNS.
Figure 1. Overview of results for the acquisition (left) and extinction (right) phases of the study. The figure 
shows mean responses per trial for US expectancy ratings (top), EMG (middle) and SCR (bottom). Error bars 
indicate ±1 standard error of the mean.
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Discussion
We tested the effects of tVNS on fear extinction learning in humans in a single-day fear conditioning procedure. 
Based on previous research6,7, we expected accelerated fear extinction after tVNS. The results showed no effect of 
tVNS on the rate of declarative fear extinction nor on any of the physiological indices of fear. We did find a small 
effect of tVNS on US expectancy ratings for CS− trials at the start of the extinction phase.
The lack of effects of tVNS on declarative fear extinction learning was unexpected, as this seems to contradict 
findings from our previous studies6,7. There they are in line, however, with a recent study which found no effects 
of tVNS on contextual fear extinction in a virtual reality environment26. The current study was designed to be 
a more highly powered conceptual replication of our previous studies. However, there were several differences 
between the paradigm of the current study and the ones used in the previous studies. First, in the current study, 
we used pictures of spiders instead of geometrical shapes as CSs. Previous studies have indicated that spiders 
and other evolutionarily relevant threat pictures may lead to stronger acquisition of fear and slower extinction 
learning32. Other changes we made to the paradigm included adding a 70 dB background noise and increasing 
the intensity of the startle probe (104 dB instead of 100 dB and 95 dB). All changes were made to promote a high 
arousal level in participants, which would lead to a stronger acquisition of fear, and – theoretically - allowing 
tVNS to make a larger difference.
In line with the expected increased arousal experienced by participants in this study, participants in the sham 
condition reported higher US expectancy ratings for CS− trials compared to previous studies. Additionally, par-
ticipants in both groups showed a strong, non-differential increase in SCR and startle responding at the start of 
the extinction phase compared to the end of the acquisition phase. These increased non-differential fear responses 
at the start of the extinction phase clearly reflect the increased apprehensiveness of participants in this study, and 
may partly explain the discrepancy in the results from this study compared to our previous studies. Considering 
that the expected working mechanism of tVNS is through the modulation of noradrenergic activity, one possible 
explanation for the lack of effects of tVNS on fear extinction learning is that the vagus nerve had been activated 
through adrenergic pathways in both conditions, as a result of the increased arousal experienced by participants in 
our current conditioning paradigm. Indeed, administration of peripheral adrenaline leads to an increased firing rate 
of vagus nerve fibers in rats39. In turn, administration of peripheral adrenaline prior to the extinction phase has been 
associated with stronger extinction learning in mice, possibly due to subsequently increased central noradrenergic 
activity40. Clearly, there is a need for more fundamental studies on the working mechanisms of tVNS in humans and 
its interactions with background levels of arousal, since this could strongly affect the clinical applicability of tVNS.
The lower initial US expectancy rating for CS− trials in the tVNS condition was an unexpected finding, 
since our previous studies found effects of tVNS on the learning rates of the CS+, not the CS−. This effect of 
tVNS on CS− ratings at the start of the extinction may simply reflect baseline differences between participants, 
independent of the experimental manipulation. Alternatively, this effect may reflect an improved ability of par-
ticipants in the tVNS condition to immediately recognize the CS− as a safety cue. This result would be in line 
with the Generalized Unsafety Theory of Stress (or GUTS41,42), which posits that vagal activity is an important 
determinant of the maintenance of prefrontal inhibition of the stress response once safety is detected. As such, 
vagus nerve activation may increase a person’s ability to identify and remember that a situation is indeed safe and 
can prevent a stress response from generalizing from a certain stimulus (e.g. the CS+) to a wider context (e.g. 
the CS−). Indeed, Fig. 1 shows a clear increase in US expectancy ratings for CS− trials at the start of the extinc-
tion phase compared to the end of the acquisition phase, indicating a generalization of the fear response and an 
increase in the uncertainty about CS−US contingencies. Even though we did not formally hypothesize this effect 
to occur based on previous findings, the results found in this study are clearly in line with the GUTS and could 
point towards an interesting therapeutic effect of tVNS. Further research is clearly warranted to test whether these 
results can be corroborated.
One could argue that groups may not have been similar on their abbreviated SPQ score, and participants in 
the tVNS condition reported slightly higher symptoms of spider phobia than the sham condition. However, it’s 
important to note that participants in both conditions scored well within the normal range and should not be 
classified as spider phobics. As such, we do not believe that differences in spider phobia are likely to explain the 
lack of effects of tVNS found in this study.
The current study included mainly female participants, which may have possibly limited the generalizability of 
the findings. Although research on this topic is limited, previous studies in animals43 and in humans44,45 have found 
no consistent differences on vagus nerve morphology between males and females. However, effects of tVNS on 
LC-NE activity may be different for men and women due to differences in morphology of the LC and CRF1 recep-
tors46. Notably, LC dendrites in female compared to male rats are longer and more complex47, which could lead to 
a stronger information relay from the NTS (the main terminal of vagal afferents) to the LC48. While these intricate 
differences in LC dendrite morphology have not yet been studied in humans, possible sex differences in the sensi-
tivity of the LC to changes in afferent signaling of the vagus to the NTS clearly warrant additional research. With 
respect to our current study, we cannot be certain whether the skewed male-to-female participant ratio has affected 
the results of our analyses. One important argument that we’ve made before6, is that not much is known about the 
optimal stimulation intensity for human auricular tVNS. The stimulation intensity used in this study (0.5 mA) is 
based on invasive VNS studies that found cognitive effects using this stimulation intensity. An important difference 
between invasive and transcutaneous VNS is that during invasive VNS, the stimulation coil is wrapped directly 
around the vagus nerve. During tVNS, the stimulation current first has to pass a layer of skin tissue before diffusely 
reaching the vagus nerve. Thus, the electrical current is impeded by skin, leading to a smaller overall electrical 
current reaching the vagus nerve and a larger between-participant variability in the amount of electrical current 
that does reach the nerve, based on inter-individual differences in impedance. These factors may have reduced the 
effects tVNS may have had on extinction learning. This further highlights the need for more fundamental studies 
of optimal stimulation intensities but also of biomarkers of afferent vagus nerve activation.
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In summary, in this study we found no indications that tVNS accelerated the extinction of conditioned fear. 
However, participants who received tVNS displayed lower US expectancy ratings to the CS− trials at the start of 
the extinction phase compared to participants in the sham condition. This effect was not expected beforehand and 
may reflect a coincidental finding. On the other hand, it is in line with the GUTS model of anxiety, which posits 
that the vagus nerve plays an integral part in recognizing safety signals in the environment. The results from this 
study clearly call for more elaborate studies which focus on the ideal tVNS stimulation settings, the comparability 
of transcutaneous and invasive VNS, and search for possible biomarkers to non-invasively assess vagus nerve 
activity in humans.
Methods
Participants. We conducted a sample size calculation beforehand to estimate the number of participants 
required to detect a medium effect size for the main effect of condition in a multilevel analysis. This calculation 
indicated that given a power of 1 − β = 0.80, a significance level of α = 0.05, 12 repeated measurements during 
the extinction phase and a minimum effect size of δ = 0.5, we needed at least 35 participants in each condition49.
Eligible participants were healthy college students between the ages of 18 and 25. Participants with spider 
phobia, epilepsy, bradycardia, cardiac arrhythmia, cardiac diseases, significant head trauma, pregnancy, drug 
use, neurological or psychiatric disorders were excluded from participating in this study. Participants received 
either course credits or 10 euro as compensation for participating in the study. The study was approved by the 
Institutional Ethical Board of Leiden University, Institute of Psychology (CEP #4782302709). The experiment was 
performed in accordance with relevant guidelines and regulations. All participants gave their written informed 
consent prior to the start of the experiment.
Stimuli and Apparatus. Stimuli. CSs were pictures of spiders (IAPS numbers 1200–1201, based on50). 
The slides were 18 cm high and 25 cm wide and were presented on a 17-inch CRT monitor in the middle of the 
screen on a black background. Both CSs were presented for 8 seconds. During the acquisition phase, one of the 
CSs was followed by the US in 75% of the trials (CS+), while the other CS was never followed by a US (CS−). 
To-be conditioned stimuli were assigned as CS+ and CS− in a counterbalanced order. The US occurred 7.5 s 
after CS+ onset. Intertrial interval durations varied randomly between 15 and 25 seconds. Presentation of CSs 
was semi-randomized, to ensure that one CS type could not be presented on more than three subsequent trials.
The US was a 20 ms electric shock that was delivered to the wrist of the non-dominant hand. A conductive gel 
was used between the electrodes and the skin. The shock was delivered using a Grass S48 stimulator. Shock inten-
sity was determined at the start of the experimental procedure. The intensity was individually set at a level that 
was very uncomfortable, but not painful. Participants received shocks of gradually increasing intensity, starting 
at 1 mA and increasing in 5 mA increments. After every shock, participants were asked to rate what they had felt 
and whether the shock intensity would have to be increased to reach a level that was ‘very uncomfortable, but not 
painful’. Once participants felt that they had reached a shock intensity that corresponded to this level, the shock 
intensity was kept stable at this level for the rest of the experiment.
The startle probe consisted of a 50 ms, 104 dB burst of white noise with near instantaneous rise time that was 
administered to both ears via headphones. Startle probes were presented 7 seconds after every CS and intertrial 
interval (ITI) onset. Throughout the acquisition and extinction phases, participants also heard a continuous back-
ground noise of 70 dB pink noise from their headphones. Both the startle probes and the continuous background 
noise were created using Audacity 2.0.2 software.
tVNS and sham stimulation. Transcutaneous vagus nerve stimulation (tVNS) is a non-invasive method of elec-
trically stimulating the afferent auricular branch of the vagus nerve located at the cymba conchae9.
We used a tVNS device that provides electrical stimulation using two titanium electrodes, positioned on top 
of a silicon earplug, which are connected by a wire to a portable neurostimulator (Nemos®, Cerbomed, Erlangen, 
Germany). The electrodes deliver 30-second waves of electrical stimulation (0.5 mA, 25 Hz, 250 μs wavelength) 
to the concha of the left outer ear51, alternated by 30-second breaks. In the sham condition, the electrodes are 
connected to the center of the earlobe instead of the concha51. The stimulation parameters (current, frequency, 
on/off cycle) were fixed for all participants. We stimulated the left ear to avoid potential cardiac effects that have 
been related to efferent vagal fibers of the right ear52 but not the left9.
Expectancy Ratings. Participants were asked to rate the extent to which they expected a shock to occur during 
every CS presentation using a visual analogue scale that ranged from 0 (‘not at all’) to 100 (‘certainly’). Participants 
were instructed to give these ratings by moving the cursor within 5 seconds after CS onset, after which the scale 
would disappear from the screen. The scale was presented at the bottom of the screen so as not to draw too much 
attention away from the stimuli. At the beginning of every new CS presentation, the slide would reappear and the 
cursor would return to the ‘uncertain’ middle position (cf.53).
Psychophysiological Measures. We measured the potentiation of the eyeblink startle reflex to an acoustic startle 
probe by using electromyography (EMG) of the left orbicularis oculi muscle. To measure the eyeblink reflex, we 
used two 4 mm Ag-AgCl Biopac electrodes, one placed below the lower left eyelid in line with the pupil in forward 
gaze, and the second one placed approximately 1 cm lateral to the first (in accordance with the guidelines specified 
in54). EMG was measured using a Biopac system, and filtered by 500 Hz low-pass and 10 Hz high-pass hardware 
filters. The EMG signal was grounded by the electrodermal electrodes. The raw response signals were visually 
checked by the first author in a blinded procedure, and trials that were affected by movement artifacts or overall 
poor signal quality were manually removed (0.5% of trials).
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EMG responses were calculated by subtracting the mean EMG signal in the 20 ms period directly follow-
ing the startle probe presentation from the maximum EMG amplitude within the response window between 
21–150 ms following startle probe onset54.
Electrodermal activity was measured using two Ag/AgCl electrodes (Biopac EL507-10). The electrodes were 
attached to the distal phalanges of the index and middle finger of the nondominant hand55.
The skin conductance response (SCR) in response to the CS was determined by subtracting the average base-
line skin conductance level (2 s before CS onset) from the peak skin conductance level in the first 6 seconds fol-
lowing CS onset. Responses lower than 0.02 micro Siemens were scored as zero and remained in the analyses56. 
SCRs were further log transformed to normalize the data distribution.
Cardiac activity. Heart rate (HR) and heart rate variability (HRV) were derived from the raw ECG signal, which 
was measured continuously using a two-lead set-up of the Biopac system. The ECG signal was grounded by the 
electrodermal electrodes. The raw ECG signal was measured at 1000 Hz and subsequently filtered using 2 Hz 
low-pass and 50 Hz high-pass software filters. The signal was subsequently visually inspected checked by the first 
author in a blinded procedure and artifacts were manually corrected. Interbeat intervals were extracted from 
the filtered signal, from which HR and the root mean square of the successive differences (RMSSD) between 
heart rates were calculated using a custom Matlab script. A five-minute baseline recording of every participant’s 
RMSSD level was used to assess participants’ vagally-mediated HRV and to check for possible differences in 
baseline vagal tone.
Questionnaires. The State Trait Anxiety Inventory (STAI) is a self-report questionnaire consisting of 2 scales 
with 20 questions each, measuring both state and trait anxiety34,57. The STAI has shown high internal consistency 
and validity57,58. The range of both scales of the STAI is between 20 and 80. Norm scores from the general popu-
lation are 33.16 for the state scale and 36.35 for the trait scale.
The Penn State Worry Questionnaire (PSWQ) is a 16-item self-report questionnaire that assesses the duration 
and uncontrollability of worry59. The PSWQ has demonstrated high reliability, temporal stability and validity in 
the assessment of trait-worry59,60. The range of the PSWQ is between 16 and 80. A PSWQ score of 62 has been 
validated as a screening tool for generalized anxiety disorders61.
The Abbreviated Spider Phobia Questionnaire (SPQ) is a self-report questionnaire consisting of 15 yes-or-no 
questions that assess the subjects fear of spiders62. Since pictures of spiders were used as conditioned stimuli, 
between groups differences in spider phobia severity may affect fear and extinction learning rates. The abbre-
viated SPQ has shown high internal consistency and strong discriminatory validity32. Scores on the abbrevi-
ated SPQ range between 0 and 15, with spider phobic participants scoring significantly higher than nonphobics 
(Mphobics = 10.31, Mnon-phobics = 2.06)32.
Participants rated their current mood (happiness, anxiety, irritableness, sadness) on a visual analogue scale 
ranging from (0) ‘not at all’ to (100) ‘completely’. The scores on these scales were converted into two comprehen-
sive scores, ‘positive affect’ (score on the happiness subscale) and ‘negative affect’ (mean score on anxiety, irrita-
bleness and sadness subscales). Visual analogue scales are brief and valid measurements of mood state63.
At the end of the experiment, participants rated potential negative side-effects as a result of the stimulation 
on a scale of 1 (“applies not at all”) to 5 (“completely applies to me”) (cf.6,7). Side-effects included in the list were 
headache, pain in the neck, nausea, muscle contractions in the face or neck, prickling sensation under the elec-
trodes, burning sensation under the electrodes and a general feeling of discomfort. Both the number of side 
effects (scores above 1 were counted as a side effect) and the mean intensity of the side effects were compared 
between the groups.
Experimental Procedure. At the start of the experimental procedure, the electrodes for EMG, SCR and 
ECG recordings was attached to the participant’s skin. The shock device was then attached to the participant’s 
non-dominant wrist, after which the shock intensity was individually determined.
Participants were told that they would see two pictures, and it was their task to learn to predict which one was 
often followed by a shock and which one was not. As such, this design included a partial instruction on CS-US 
contingencies, which leads to a more uniform fear learning compared to a uninstructed fear study, while still leav-
ing enough room for associative learning to take place64. Prior to the start of the acquisition phase, a five-minute 
baseline measurement of every participant’s RMSSD level was recorded to assess participants’ vagally-mediated 
HRV, during which time participants watched a muted neutral film clip.
We included a habituation phase prior to the acquisition phase to ensure that participants habituated to the 
stimuli used in the paradigm prior to differential associative fear learning64. Participants were informed that in 
this phase, they would be introduced to the different stimuli that would be presented in the rest of the task. First, 
we presented both CS pictures once. Subsequently, we presented 10 startle probes over a period of 150 seconds to 
habituate startle blink responses. During this period, participants were also habituated to the background noise, 
which would stay on for the remainder of the Acquisition and Extinction sessions, although it was temporarily 
switched off while participants filled in questionnaires and while the tVNS device was attached.
During the acquisition phase, both the CS+ and the CS− were presented eight times. The acquisition phase 
for every participant started with a CS− trial, followed by a CS+ trial. The CS+ was followed by the US in 75% of 
the trials – specifically, the first and the fifth presentation were always unreinforced (cf.50,65). The CS− was never 
followed by a shock.
At the end of the acquisition phase, participants were asked to rate the unpleasantness of the US on a scale 
from 0 (not unpleasant at all) to 100 (very unpleasant).
After the acquisition phase, we attached the tVNS device to the ear of the participant and we started either 
tVNS or sham stimulation. Participants were sequentially assigned to receive either tVNS or sham stimulation 
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to reduce the odds of unbalanced group sizes. Regardless of experimental allocation, participants were told that 
stimulation was expected to affect physiological processes during the tasks. Participants wore the nerve stimula-
tor throughout the rest of the experimental procedure. Prior fMRI studies have noted a temporal latency in the 
neurological effects of tVNS10, which is why we instructed participants to complete a short demographics ques-
tionnaire and several other questionnaires with the tVNS device in place and active, before starting the extinction 
phase. Completing the questionnaires took roughly 12 minutes.
The extinction phase consisted of 12 presentations of both CS+ and CS− trials. Both CS types were unre-
inforced during the extinction phase. At the end of the extinction phase, participants reported any potential 
side-effects from the nerve stimulation procedure. Afterwards, the tVNS device was removed from the partici-
pant’s ear. On average, the experimental session lasted roughly 50 minutes, during which participants received 
electrical stimulation to their ear for roughly 25 minutes. See Fig. 2 for an overview of the experimental procedure.
Statistical Analyses. Between-group differences on all baseline questionnaires and baseline HRV data were 
analyzed using independent samples t-tests.
Multilevel mixed model analyses were used to assess whether the conditioning procedure resulted in success-
ful fear learning in our participants in terms of both self-reports and physiological outcomes. After we ascertained 
that participants showed a significant response differentiation between CS− and CS+ trials on an index of fear 
during acquisition, we continued to use multilevel mixed model analyses to analyze the effects of tVNS during 
the extinction phase.
All multilevel mixed models were created using maximum likelihood modeling. We allowed intercepts to vary 
randomly across participants. Adding random slopes did not improve model fit and were thus removed from all 
models. We modeled the error covariance structure of the repeated measurements (every trial was nested within 
CStypes, which were in turn nested within individual participants) by specifying a heterogeneous AR1 autore-
gressive structure.
The independent variable Trial, signifying trial number within each session, was group mean centered around 
the first trial of every phase. CStype was dummy-coded, using CS− trials as the reference category for SCR and 
US expectancy ratings and using CS+ trials as the reference category for EMG, to allow comparisons of CS+ 
trials with both CS− trials and ITI.
To account for possible non-linear learning rates, we fitted linear and loglinear time curves to all models, as we 
did previously6,7, and removed either of these variables if this resulted in better model fit according to BIC estimates.
Cohen’s d effect sizes were calculated for significant effects of tVNS using the formula d
S
b
pooled D
=
′
 where b 
denotes the regression coefficient of the corresponding effect and SD corresponds to the pooled within-group 
standard deviation66.
All analyses concerning the effects of tVNS on extinction learning are reported as one-tailed tests to increase 
our power to detect an effect in the direction we expected. Analyses were conducted using the nlme and lmerTest 
packages in R.
Additionally, we performed post-hoc Bayesian re-analyses of the effects of tVNS during the extinction phase. 
The results of these re-analyses support the main analyses and are presented in a Supplementary file.
The datasets analyzed during the current study are available on the Open Science Framework, osf.io/p2wfc.
Figure 2. Experimental Overview. (1) The overall experiment lasted approximately 45 minutes and could 
be broadly subdivided into a baseline phase, an acquisition phase, a phase where participants filled in some 
questionnaires and finally an extinction phase. Participants received tVNS or sham stimulation only in the last 
two phases. (2) Every trial lasted 8 seconds in total. Participants were asked to rate to what extent they expected 
a shock to occur within the first 5 seconds of CS onset (response window A). Maximum skin conductance 
responses were recorded within the first 6 seconds (response window B) and maximum startle responses were 
recorded within 21–150 ms after startle probe onset (response window C).
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